Prophylactic fluconazole in preterm neonates [4]

New England Journal of Medicine

Volumn 357, Issue 13, 2007, Pages 1348-1349

  Vain, Nestor E ^a   Vazquez, Liliana N ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Sanatorio de la Trinidad   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; FLUCONAZOLE;

ANTIBIOTIC THERAPY; CANDIDIASIS; CONTROLLED STUDY; HUMAN; INCIDENCE; INFANT; INFECTION RATE; INVASIVE CANDIDIASIS; LETTER; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN CARE; NEWBORN INFECTION; NEWBORN SEPSIS; PREMATURITY; PRIORITY JOURNAL; SKIN CARE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34748916935     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc071984     Document Type: Letter

References (5)

1. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007;356:2483-95.
2. Makhoul IR, Bental Y, Weisbrod M, et al. Candidal versus bacterial late-onset sepsis in very low birthweight infants in Israel: a national survey. J Hosp Infect 2007;65:237-43.
3. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110:285-91.
4. Cotten CM, McDonald S, Stoll B, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics 2006;118:717-22.
5. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.